Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.51 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.49 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.48 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 2/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL951932 | 1.00 | ALDH1A1 (0.57) | ALDH1A1MAPK8GRM2GRM3BCHE | |
| SCHEMBL4205757 | 0.94 | ALDH1A1 (0.59) | ALDH1A1MAPK8BCHEACHEBACE1 | |
| SCHEMBL27661575 | 0.90 | OPRL1 (0.52) | ALDH1A1SCN9A | |
| SCHEMBL653533 | 0.86 | ALDH1A1 (0.48) | ALDH1A1MAPK8EPHX2ANO1SCN9A | |
| SCHEMBL30933805 | 0.85 | AHCY (0.48) | ALDH1A1MAPK8ANO1SCN9A | |
| SCHEMBL652820 | 0.84 | HTT (0.53) | ALDH1A1MAPK8BCHEACHEBACE1 | |
| SCHEMBL651891 | 0.84 | HTT (0.53) | ALDH1A1MAPK8BCHEACHEBACE1 | |
| SCHEMBL4329719 | 0.84 | ALDH1A1 (0.56) | ALDH1A1MAPK8EPHX2CNR1CYP2C9 | |
| SCHEMBL31282805 | 0.84 | MAPK8 (0.49) | ALDH1A1MAPK8EPHX2ANO1CNR1 | |
| SCHEMBL4477584 | 0.83 | BCHE (0.58) | GRM2GRM3BCHEACHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868014-B2 | 1-(hetero)aryl-3-amino-pyrrolidine derivatives for use as mGluR3 antagonists | ELI LILLY AND COMPANY (US) | 2011-01-11 | — | — | US | disclosed |
| EP-1805165-B1 | 1-(HETERO)ARYL-3-AMINO-PYRROLIDINE DERIVATIVES FOR USE AS MGLUR3 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-12-16 | — | — | EP | disclosed |
| US-20080300266-A1 | 1-(Hetero)Aryl-3-Amino-Pyrrolidine Derivatives for Use as Mglur3 Antagonists | ELI LILLY AND COMPANY (US) | 2008-12-04 | — | — | US | disclosed |
| EP-1805165-A1 | 1-(HETERO)ARYL-3-AMINO-PYROLLIDINE DERIVATIVES FOR USE AS MGLUR3 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006044454-A1 | 1-(HETERO)ARYL-3-AMINO-PYROLLIDINE DERIVATIVES FOR USE AS MGLUR3 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300266-A1 | 1-(Hetero)Aryl-3-Amino-Pyrrolidine Derivatives for Use as Mglur3 Antagonists | GRM3, GRM1, GRIA3 | ALDH1A1 3907/4885MAPK8 3678/4885GRM2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.